Hence, the authors suggest that partial antagonism of endogenous GM-CSF by miR-155 inhibition might prove to be a novel therapeutic for the treatment of rheumatoid arthritis and other chronic inflammatory diseases. Here, CSF2 is linked to rheumatoid arthritis.